Drug spray helps treat premature ejaculation, finds study
In two remarkable researches, scientists have found a new drug to be highly effective in curing men’s premature ejaculation (PE).
Results of National Healthand Social Life Survey along with research conducted by University of California, U.S., established that PSD502 spray is effective in curing PE.
The desensitizing drug PSD502 is a combination of two available drugs--lidocaine and prilocaine.
The Telegraph quoted Dr. Ira Sharlip, clinical professor, urology atUniversity of California as saying, “Combined results from the PSD502 pivotal studies are very exciting and this is a significant milestone.”
Research details
Researchers gathered data from across 70 centers in the United States, Canada, and Europe, evaluating men who had PE.
The three-month study was conducted on 556 (randomized) and 536 (treated) men, with primary PE.
For the study, two-thirds of the participants were given PSD502, and one-third were given a placebo. The spray was applied using a metered dose five minutes before intercourse.
PSD502 is proprietary formulation of Shionogi Pharma, Inc., a U.S.-based group of Shionogi and Co., Ltd.
Results of the studies
Researchers found that males using PSD502 were able to sustain an erection 5.5 times longer than those given a placebo.
The former group also reported better ejaculatory control and overall satisfaction, stated researchers.
However, this group also reported 6.1 percent side-effects compared to 0.6 percent of the control group.
Besides, five percent of the men’s sexual partners complained of vulvovaginal burning.
The spray medication will have to undergo further examinations to be accepted as a pivotal PE treatment, stated researchers.
Lack of accurate data
Researchers further stated that there is lack of accurate data as regards PE.
One reason could be that an extensive definition of PE has only recently been revealed. Secondly, a number of men do not report this problem to their general practitioner.
Emax Health provides the definition of PE as established by the International Society for Sexual Medicine, “A male sexual dysfunction characterized by ejaculation which is always or nearly always occurs prior to or within one minute of vaginal penetration; and an inability to delay ejaculation on all or nearly all vaginal penetrations, and negative personal consequences, such as distress, bother, frustration, and/or the avoidance of sexual intimacy.”
According to the National Health and Social Life Survey, 21 percent of men between the age-group of 18 to 59 experience premature ejaculation.
The findings were presented at the 2010 American Urological Association Annual Mee
No comments:
Post a Comment